HK1115324A1 - Therapeutic agent for disease with apoptotic degeneration in eye tissue cell containing pedf and fgf2 - Google Patents

Therapeutic agent for disease with apoptotic degeneration in eye tissue cell containing pedf and fgf2

Info

Publication number
HK1115324A1
HK1115324A1 HK08111109.7A HK08111109A HK1115324A1 HK 1115324 A1 HK1115324 A1 HK 1115324A1 HK 08111109 A HK08111109 A HK 08111109A HK 1115324 A1 HK1115324 A1 HK 1115324A1
Authority
HK
Hong Kong
Prior art keywords
fgf2
disease
therapeutic agent
cell containing
eye tissue
Prior art date
Application number
HK08111109.7A
Original Assignee
Dnavec Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Corp filed Critical Dnavec Corp
Publication of HK1115324A1 publication Critical patent/HK1115324A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK08111109.7A 2005-02-23 2008-10-08 Therapeutic agent for disease with apoptotic degeneration in eye tissue cell containing pedf and fgf2 HK1115324A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005048064 2005-02-23
PCT/JP2006/303052 WO2006090697A1 (en) 2005-02-23 2006-02-21 Therapeutic agent for disease with apoptotic degeneration in eye tissue cell containing pedf and fgf2

Publications (1)

Publication Number Publication Date
HK1115324A1 true HK1115324A1 (en) 2008-11-28

Family

ID=36927337

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08111109.7A HK1115324A1 (en) 2005-02-23 2008-10-08 Therapeutic agent for disease with apoptotic degeneration in eye tissue cell containing pedf and fgf2

Country Status (4)

Country Link
JP (1) JP4971974B2 (en)
CN (1) CN101160139B (en)
HK (1) HK1115324A1 (en)
WO (1) WO2006090697A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012126369A1 (en) * 2011-03-22 2012-09-27 北京三诺佳邑生物技术有限责任公司 Dna, recombinant vector containing the same, cell, composition and use thereof
CN103060378A (en) * 2011-10-24 2013-04-24 四川百利药业有限责任公司 Preparation method of SIV (simian immunodeficiency virus) vector
CN103316356B (en) 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 A kind of recombined lentivirus vector preparation
CN102788883B (en) * 2012-08-30 2014-11-05 重庆医科大学 Kit for detecting depression
WO2015053398A1 (en) * 2013-10-11 2015-04-16 タカラバイオ株式会社 High-titer retrovirus vector

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002101057A1 (en) * 2001-06-08 2004-09-24 株式会社ディナベック研究所 Gene transfer into primate embryonic stem cells using VSV-G pseudotyped simian immunodeficiency virus vector

Also Published As

Publication number Publication date
JPWO2006090697A1 (en) 2008-07-24
CN101160139A (en) 2008-04-09
CN101160139B (en) 2011-10-12
JP4971974B2 (en) 2012-07-11
WO2006090697A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
GB0523576D0 (en) Drug composition and its use in therapy
HK1117154A1 (en) Benzoquinazoline derivatives and their use in treating bone disorders
PL3524261T3 (en) Exendin for use in treating diabetes and reducing body weight
GB2437875B (en) Skin care composition comprising L-carnosine and N-acetylcysteine
EP1895946A4 (en) Improvements relating in and to surgical implants
EP1766768A4 (en) Use of lacritin in promoting ocular cell survival
EP1868656A4 (en) Bioactive stents for type ii diabetics and methods for use thereof
PL2359701T3 (en) Composition for improving membrane composition and functioning of cells for use in the treatment of allergy
EP2155235A4 (en) Oxygen-generating compositions for enhancing cell and tissue survival in vivo
EP1908011A4 (en) Reconstruction stabilizer and active vision
EP1737379A4 (en) Bioactive stents for type ii diabetics and methods for use thereof
EP1868430A4 (en) Composition and method for in vitro preservation of corneal tissues
EP1884234A4 (en) Prophylactic or therapeutic agent for corneal and conjunctival disorder
IL192206A0 (en) Topical mecamylamine formulations for ocular administration and uses thereof
HK1115324A1 (en) Therapeutic agent for disease with apoptotic degeneration in eye tissue cell containing pedf and fgf2
HK1112848A1 (en) Pharmaceutical composition for regenerating myofibers in the treatment of muscle injuries
GB2431356B (en) Improvements in and relating to disposable dispensers for personal use
EP1933853A4 (en) Tissue disruption treatment and composition for use thereof
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
IL186634A0 (en) Compositions facilitating drug penetration and drug retention in skin
IL185586A0 (en) 1,2,4-triazine derivatives, preparation and use thereof in human therapy
EP2034829A4 (en) Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association
GB0523166D0 (en) Improvements in and relating to medical products
GB0523577D0 (en) Drug composition and its use in therapy
GB0523578D0 (en) Drug composition and its use in therapy

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20081128: (72)

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160221